Notice Number: NOT-DA-16-006
Key Dates
Release Date: December 4, 2015
Estimated Publication Date of Announcement: January 2016
First Estimated Application Due Date: February 2016
Earliest Estimated Award Date: September 2016
Earliest Estimated Start Date: November 2016
Issued by
National Institute on Drug Abuse (NIDA)
Purpose
The National Institute on Drug Abuse intends to reissue the Funding Opportunity Announcement (FOA) PA-13-015 "Prescription Drug Abuse (R01)" to encourage applications for research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues will be encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors will be encouraged, as will be studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers will be further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in January 2016 with an expected application due date in February 2016.
This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.
This Notice encourages investigators with expertise and insights into this area of science to begin to consider applying for this new FOA.
In addition, collaborative investigations combining expertise in multiple scientific disciplines will be encouraged and these investigators should also begin considering applying for this application.
Among the areas of research encouraged in this initiative are basic and clinical research examining the mechanisms that underlie the effects of prescription drug abuse as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of prescription drug abuse.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Please direct all inquiries to:
David Thomas, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1313
Email: [email protected]